'Zepbound Sheds More Weight Than Wegovy, Study Finds' - Forbes
'Zepbound Sheds More Weight Than Wegovy, Study Finds' - Forbes
'Zepbound比Wegovy減重更多，研究發現' - Forbes
Eli Lilly's popular obesity injection Zepbound trounces Novo Nordisk's Wegovy when it comes to shedding weight, according to new research published Monday, intensifying competition between the two pharma giants as they compete for the lucrative drug market and dig in to defend their dominant positions against an array of hopeful rivals rushing to market.
根據本週一發佈的新研究，伊利莎白·莉莉(Eli Lilly)流行的減肥注射劑Zepbound在減肥方面超過了諾和諾德(Novo Nordisk)的Wegovy，這加劇了這兩個製藥巨頭之間的競爭，他們在爭奪利潤豐厚的藥品市場的同時，抵禦着一系列抱有希望襲來的競爭對手。
Obese and overweight adults taking tirzepatide (the generic name for Zepbound and Mounjaro) lost more weight and lost it faster than adults taking semaglutide (the generic name for Wegovy and Ozempic) according to new peer reviewed research published in JAMA Internal Medicine.
根據《美國醫學會內科學雜誌》(JAMA Internal Medicine)最新的同行評審研究發現，服用 鈉 逃酰肽(Tirzepatide，即Zepbound和Mounjaro的通用名)的超重和肥胖成年人比服用血糖調節肽(Semaglutide，即Wegovy和Ozempic的通用名)的成年人更快地減肥。
While most...
研究...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。